Page last updated: 2024-12-06

tolrestat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tolrestat is a potent and selective inhibitor of aldose reductase, an enzyme that plays a crucial role in the development of diabetic complications. It is studied extensively as a potential treatment for diabetic neuropathy, a debilitating condition that affects nerve function in people with diabetes. The synthesis of tolrestat involves a complex multi-step process and is known to have various effects on the body, including reducing the accumulation of sorbitol, a toxic sugar alcohol, in nerve cells. Tolrestat has shown promise in clinical trials, demonstrating its effectiveness in slowing the progression of diabetic neuropathy. However, it is important to note that tolrestat can also cause side effects, such as liver damage and anemia. Ongoing research focuses on optimizing its therapeutic potential while minimizing its adverse effects.'

tolrestat: RN & structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53359
CHEMBL ID436
CHEBI ID48549
SCHEMBL ID49326
MeSH IDM0120716

Synonyms (58)

Synonym
ay-27773
alredase
lorestat
alrestin
tolrestatin
tolrestatum [latin]
ay 27773
ay-27,773
n-(6-methoxythio-5-(trifluoromethyl)-1-naphthoyl)sarcosine
glycine, n-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-n-methyl-
tolrestat
C01621
82964-04-3
TOL ,
DB02383
D02323
alredase (tn)
tolrestat (usan/inn)
bdbm16314
2-{[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]-n-methylmethanethioamido}acetic acid
chembl436 ,
n-{[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]carbonothioyl}-n-methylglycine
tolrestatum
CHEBI:48549 ,
n-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-n-methylglycine
n-{[6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbonothioyl}-n-methylglycine
AKOS005146007
2-[[6-methoxy-5-(trifluoromethyl)naphthalene-1-carbothioyl]-methylamino]acetic acid
unii-0t93lg5nmk
tolrestat [usan:inn:ban]
0t93lg5nmk ,
BCPP000039
[(6-methoxy-5-trifluoromethyl-naphthalene-1-carbothioyl)-methyl-amino]-acetic acid
n-((6-methoxy-5-(trifluoromethyl)naphthalen-1-yl)thioxomethyl)-n-methylglycine
gtpl7404
HY-16500
CS-2040
SCHEMBL49326
tolrestat [who-dd]
tolrestat [usan]
n-[6-methoxythio-5-(trifluoromethyl)-1-naphthoyl]sarcosine
tolrestat [mart.]
tolrestat [mi]
tolrestat [inn]
n-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-n-methylglycine
2-(6-methoxy-n-methyl-5-(trifluoromethyl)naphthalene-1-carbothioamido)acetic acid
n-[[6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-n-methylglycine
[([6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbothioyl)(methyl)amino]acetic acid #
glycine, n-[[6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-n-methyl-
n-(6-methoxy-5-(trifluoromethyl)naphthalene-1-carbonothioyl)-n-methylglycine
J-522752
2-{1-[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]-n-methylmethanethioamido}acetic acid
DTXSID80904890
FT-0753651
BCP02377
Q7814620
A13083
VS-0127

Research Excerpts

Overview

Tolrestat is a well tolerated nonhydantoin aldose reductase inhibitor that has been reported to improve nerve conduction in diabetic animals and humans. It is undergoing extensive clinical investigation for the treatment of diabetic complications including polyneuropathy.

ExcerptReferenceRelevance
"Tolrestat is a well tolerated nonhydantoin aldose reductase inhibitor that has been reported to improve nerve conduction in diabetic animals and humans. "( Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Beg, M; Bochenek, WJ; Brown, MB; Gonen, B; Graepel, GJ; Greene, DA; Hicks, D; Hohman, TC; Sima, AA,
)
1.82
"Tolrestat is an aldose reductase inhibitor undergoing clinical trials in diabetic subjects that may reduce the severity of chronic tissue damage associated with hyperglycemia. "( Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes.
Battle, M; Chiang, S; Fruncillo, R; Hicks, D; Kraml, M; Mayersohn, M; Parker, V; Troy, S, 1996
)
1.99
"Tolrestat is an aldose reductase inhibitor that is undergoing extensive clinical investigation for the treatment of diabetic complications including polyneuropathy. "( Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.
Lemkes, HH; van Dijk, JG; van Gerven, JM,
)
1.89

Effects

ExcerptReferenceRelevance
"Tolrestat has been used as a standard aldose reductase inhibitor to dissect out polyol pathway-dependent mechanisms in many experimental studies; however, doubt has been cast upon its ability to prevent nerve conduction velocity deficits in diabetic rats."( Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
Cameron, NE; Cotter, MA; Hohman, TC, 1998
)
1.24

Treatment

Tolrestat (15 mg x kg) diminished intimal hyperplasia and decreased SMC content of the lesion by 25%. Treatment with tolrestat completely prevented this impairment in afferent arteriolar responsiveness. Tolrestat treatment for 4 weeks in 17 patients restored the reduced NRBA to an almost normal level.

ExcerptReferenceRelevance
"Tolrestat treatment for 4 weeks in 17 patients restored the reduced NRBA to an almost normal level (relative NRBA, 0.55 +/- 0.20 v 0.99 +/- 0.36, P < .05) despite the fact that FPG level did not change (11.8 +/- 2.8 v 11.4 +/- 2.8 mmol/L)."( Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients.
Ihm, SH; Park, CJ; Park, SW; Yoo, HJ, 1997
)
1.42
"Tolrestat treatment increased GSH levels (P < .05 v placebo and baseline) and the NADPH/tNADP ratio (P < .05 v placebo and baseline)."( Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients.
Basili, S; Bravi, MC; Cassone-Faldetta, M; De Mattia, G; Ferri, C; Laurenti, O; Pietrangeli, P, 1997
)
1.02
"Treatment with tolrestat (15 mg x kg(-1) x day(-1)) diminished intimal hyperplasia and decreased SMC content of the lesion by 25%."( Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells.
Bhatnagar, A; Ramana, KV; Srivastava, S; Srivastava, SK; Tammali, R, 2006
)
0.67
"Treatment with tolrestat completely prevented this impairment in afferent arteriolar responsiveness (-16.5 +/- 1.8%; p < 0.001)."( Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.
Epstein, M; Forster, HG; Hohman, TC; ter Wee, PM, 1996
)
0.85

Toxicity

ExcerptReferenceRelevance
" The drug was only slightly toxic to BRP but induced morphological changes in pericytes with the loss of cellular processes and decreased cell spreading."( The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes.
Chibber, R; Kohner, EM; Mirlees, D; Molinatti, PA; Wong, JS, 1994
)
0.57

Pharmacokinetics

Tolrestat disposition was characterized by first-order absorption and biexponential disposition. In normal subjects the terminal disposition half-life (t1/2) was 13 +/- 3 hours. However, tolrestat clearance was significantly reduced from 30 +/- 3 (SD) ml/hr/kg in the normal subjects to 15 +/- 5 ml/hour in subjects receiving dialysis.

ExcerptReferenceRelevance
" However, tolrestat clearance was significantly reduced from 30 +/- 3 (SD) ml/hr/kg in the normal subjects to 15 +/- 5 ml/hr/kg in the subjects receiving dialysis, and tolrestat half-life was prolonged from 11 to 16 hours."( The effect of renal disease on tolrestat pharmacokinetics.
Chiang, ST; Conrad, K; Hicks, DR; Kraml, M; Troy, SM, 1992
)
0.97
" Tolrestat was administered by gavage (1 x 150 mg/kg, or 5, and 15 mg/kg/day for 15 days to attain steady state as estimated from the 53-h half-life of tolrestat determined in rat nerve); subsequently, at six time intervals, ranging from 4 to 59 days, rats were given access for 4 days to a 20% galactose diet, and killed."( Tolrestat pharmacokinetics in rat peripheral nerve.
Dvornik, D; Hicks, DR; Kraml, M; Millen, J,
)
2.48
"To examine the effect of diabetes mellitus on the pharmacokinetics of tolrestat and to investigate its effect on red blood cell sorbitol levels according to a new pharmacodynamic model for this class of drugs."( Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes.
Chiang, ST; Cohen, AF; Jusko, WJ; Kroon, R; Lemkes, HH; van Griensven, JM; Verhorst, CJ, 1995
)
1.97
"Tolrestat disposition was characterized by first-order absorption and biexponential disposition: In normal subjects the terminal disposition half-life (t1/2) was 13 +/- 3 hours (mean +/- SD) and the apparent oral clearance (CL/F) was 48 +/- 9 ml/hr/kg, similar to the values in patients with type I diabetes mellitus (t1/2 = 14 +/- 4 hours; CL/F = 55 +/- 10 ml/hr/kg)."( Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes.
Chiang, ST; Cohen, AF; Jusko, WJ; Kroon, R; Lemkes, HH; van Griensven, JM; Verhorst, CJ, 1995
)
3.18
" The simulations reveal that the expanded models exhibit most properties of basic indirect response models, such as slow response initiation, lag time between the kinetic and dynamic peaks, a large dose plateau, and shift in Tmax with dose."( Assessment of basic indirect pharmacodynamic response models with physiological limits.
Jusko, WJ; Krzyzanski, W; Yao, Z, 2006
)
0.33

Bioavailability

Renal dysfunction had no apparent effect on the rate of absorption or volume of distribution. The bioavailability of tolrestat was 81% in rats and 68% in dogs.

ExcerptReferenceRelevance
" Renal dysfunction had no apparent effect on the rate of absorption or volume of distribution of tolrestat."( The effect of renal disease on tolrestat pharmacokinetics.
Chiang, ST; Conrad, K; Hicks, DR; Kraml, M; Troy, SM, 1992
)
0.79
" It was well absorbed in diabetic patients, resulting in high blood level, showed a highly favorable plasma half-life (27."( Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
Aldinger, CE; Beyer, TA; Dee, MF; Larson, ER; Mylari, BL; Siegel, TW; Singleton, DH; Zembrowski, WJ, 1991
)
0.28
" The bioavailability of tolrestat was 81% in rats and 68% in dogs."( Metabolic disposition and pharmacokinetics of the aldose reductase inhibitor tolrestat in rats, dogs, and monkeys.
Cayen, MN; Dvornik, D; Ferdinandi, ES; Greselin, E; Hicks, DR; Kraml, M,
)
0.67
" Our results demonstrate the systemic bioavailability of tolrestat and its aldose reductase inhibitory activity in erythrocytes of patients with diabetes."( Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes.
Challis, P; Dvornik, D; Gonzalez, R; Hicks, D; Mullane, JF; Raskin, P; Rosenstock, J; Ryder, S; Smith, T, 1985
)
0.92
"The clinical efficacy of an aldose reductase (AR) inhibitor in diabetic polyneuropathy depends on its bioavailability at the site(s) of AR in peripheral nerves."( Tolrestat pharmacokinetics in rat peripheral nerve.
Dvornik, D; Hicks, DR; Kraml, M; Millen, J,
)
1.57

Dosage Studied

The effect of the aldose reductase inhibitor, tolrestat, on red blood cell (RBC) sorbitol levels was studied in 23 patients with diabetes.

ExcerptRelevanceReference
" The low plasma AA concentration of diabetic rats can be normalized by dietary AA supplement (20-40 mg/day), a dosage approximately equal to the maximal synthetic rate of this substance in the rats."( Deficiency of ascorbic acid in experimental diabetes. Relationship with collagen and polyol pathway abnormalities.
Capogreco, C; Fisher, E; Heffernan, S; McLennan, S; Ross, GR; Turtle, JR; Yue, DK, 1988
)
0.27
" Serum concentrations of tolrestat and of total 14C were measured after dosing normal subjects and subjects with diabetes with 14C-labeled tolrestat."( Tolrestat kinetics.
Cayen, MN; Dubuc, J; Dvornik, D; Hicks, DR; Kraml, M; Ryder, S, 1984
)
2.01
" It was found that at the same dosage of 10 mg/kg/day, both AL01576 and AL04114 completely prevented all morphological and biochemical changes in the lenses of naphthalene-fed rats."( Inhibition of naphthalene cataract in rats by aldose reductase inhibitors.
Lou, MF; Xu, GT; York, B; Zigler, S, 1996
)
0.29
"45 mug equiv/g, respectively, when dosed with [(14)C]lidorestat at 10 mg/kg po)."( Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Dicioccio, AT; Geraci, LS; Gunn, DE; Jacot, JL; Jones, JH; Jones, ML; Mitschler, A; Petrova, T; Podjarny, AD; Sawicki, DR; Sredy, J; Van Zandt, MC, 2005
)
0.33
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 1.1.1.21 (aldehyde reductase) inhibitorAn EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of aldehyde reductase (EC 1.1.1.21).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B10Homo sapiens (human)IC50 (µMol)0.02440.00101.94459.6000AID1465691; AID1802103; AID1802104; AID318822; AID489631
Aldo-keto reductase family 1 member B10Homo sapiens (human)Ki0.05000.04602.16066.0000AID697009
Bile salt export pumpHomo sapiens (human)IC50 (µMol)185.30000.11007.190310.0000AID1449628
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)11.35010.00041.877310.0000AID1478797; AID1478798; AID318837; AID34804; AID34964; AID34969; AID34975; AID95257
Aldo-keto reductase family 1 member A1Homo sapiens (human)IC50 (µMol)1.15330.00502.78569.9000AID1797506; AID242605; AID489639
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)0.23030.00101.191310.0000AID1465692; AID1797506; AID1802103; AID242668; AID322413; AID34201; AID34627; AID34637; AID35131; AID489638
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.09600.00021.874210.0000AID35134
Aldo-keto reductase family 1 member B1Bos taurus (cattle)IC50 (µMol)0.04300.00702.589210.0000AID34205; AID34213; AID34325; AID34326; AID34339; AID34505; AID35134
Aldo-keto reductase family 1 member A1Sus scrofa (pig)IC50 (µMol)1.36500.00051.66804.0000AID34179; AID367704
Aldo-keto reductase family 1 member A1Rattus norvegicus (Norway rat)IC50 (µMol)1.21000.02801.13782.3200AID34196
Aldo-keto reductase family 1 member B1Sus scrofa (pig)IC50 (µMol)5.34830.01500.61352.5000AID241043; AID34668; AID34780
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.03000.00020.660310.0000AID241043
Aldo-keto reductase family 1 member C21Mus musculus (house mouse)IC50 (µMol)48.00006.90006.90006.9000AID322409
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (44)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
farnesol catabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B10Homo sapiens (human)
cellular detoxification of aldehydeAldo-keto reductase family 1 member B10Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
lipid metabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
glucuronate catabolic process to xylulose 5-phosphateAldo-keto reductase family 1 member A1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member A1Homo sapiens (human)
D-glucuronate catabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member A1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
aldehyde catabolic processAldo-keto reductase family 1 member A1Homo sapiens (human)
cellular detoxification of aldehydeAldo-keto reductase family 1 member A1Homo sapiens (human)
glutathione derivative biosynthetic processAldo-keto reductase family 1 member A1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
retinol metabolic processAldo-keto reductase family 1 member B1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B10Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
geranylgeranyl reductase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
indanol dehydrogenase activityAldo-keto reductase family 1 member B10Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B10Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
all-trans-retinol dehydrogenase (NAD+) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
aldo-keto reductase (NADPH) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member A1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member A1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member A1Homo sapiens (human)
glucuronolactone reductase activityAldo-keto reductase family 1 member A1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member A1Homo sapiens (human)
S-nitrosoglutathione reductase (NADH) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
S-nitrosoglutathione reductase (NADPH) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
methylglyoxal reductase (NADPH) (acetol producing) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member A1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
extracellular regionAldo-keto reductase family 1 member B10Homo sapiens (human)
lysosomeAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B10Homo sapiens (human)
mitochondrionAldo-keto reductase family 1 member B10Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member A1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member A1Homo sapiens (human)
synapseAldo-keto reductase family 1 member A1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member A1Homo sapiens (human)
apical plasma membraneAldo-keto reductase family 1 member A1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member A1Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (214)

Assay IDTitleYearJournalArticle
AID468493Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QID after 15 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID189602Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 152003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID176721Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 14 days in sciatic nerve1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
AID489640Selectivity ratio of IC50 for human AR to IC50 for AKR1B102010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID230204Inhibitory Activity ratio (IC50 ratio) calculated by Human recombinant aldose reductase wild type against Mutant Aldose reductase (W20A).2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID34475Inhibition of aldose reductase in partially purified bovine lens preparation at 10e-6 M.1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
AID189597Effect of the treatment on day 21 with ophthalmic solution (3%) on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID408627Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 11 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID182398In vivo inhibition of galactitol accumulation in sciatic nerves of rat at 6 mg/kg/day1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID242605In vitro inhibition of recombinant human aldehyde reductase2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID189598Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 112003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID408381Inhibition of ALR1 in Sprague-Dawley rat kidney by spectrophotometry2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID189576Effect of the treatment on day 11 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID189588Effect of the treatment on day 17 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID322409Inhibition of mouse recombinant AKR1C212008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.
AID34354In vitro aldose reductase inhibitory activity measured by NADPH-dependent inhibition of glyceraldehyde reduction in a partially purified bovine lens preparation at 10E-6 M1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
AID189604Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 172003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID93598Inhibitory activity on sorbital accumulation in human retinal cells was determined2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.
AID230202Inhibitory Activity ratio (IC50 ratio) calculated by Human recombinant aldose reductase wild type against Mutant Aldose reductase (W111A)2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID189592Effect of the treatment on day 19 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID189587Effect of the treatment on day 16 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID697008Inhibition of N-terminal 6His-tagged human AKR1B10 overexpressed in human HeLa cells assessed as inhibition of [1-14C]farnesol reduction pretreated for 2 hrs before [1-14C]farnesol challenge measured after 6 hrs2011Journal of natural products, May-27, Volume: 74, Issue:5
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID468484Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 16 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID230203Inhibitory Activity ratio (IC50 ratio) calculated by Human recombinant aldose reductase wild type against Mutant Aldose reductase (W111Y).2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID187317Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 202003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID176719Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 14 days in RBC1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID189593Effect of the treatment on day 19 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID34668In vitro inhibitory activity against aldose reductase in porcine lens.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID189596Effect of the treatment on day 21 with ophthalmic solution (1%) on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID408626Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 21 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID34213In vitro inhibition of aldose reductase from the partially purified bovine lens1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
(Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID203732In vitro inhibitory activity against sorbitol dehydrogenase (SD) from sheep liver; Not active2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID189583Effect of the treatment on day 14 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID318822Inhibition of retinaldehyde reductase activity of human AKR1B102007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID183235Inhibition of galactitol accumulation in lens of rats, by 26 mg/kg of compound1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Computer-assisted design and synthesis of novel aldose reductase inhibitors.
AID468486Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 18 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID95257In vitro inhibitory activity against L-Hexonate Dehydrogenase (L-HDH) from rat kidney (RK)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors.
AID35130Compound was evaluated In vitro for inhibition of aldose reductase activity by 50% in rat RBC1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
AID184336In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in diaphragm at 6 mg/Kg/day1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
AID408629Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 13 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID187329Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 212003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID34351In vitro % decrease of aldose reductase measured in isolated partially purified bovine lens preparations at 10e-7 M concentration1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID34975In vitro inhibition of Aldose reductase (AR) from rat lens (RL)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors.
AID697024Cytotoxicity against human HT-29 cells at 30 uM after 96 hrs by trypan blue exclusion assay2011Journal of natural products, May-27, Volume: 74, Issue:5
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
AID408632Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 16 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID34325In vitro inhibition of aldose reductase in partially purified bovine lens preparation at a concentration of 10e -8M.1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Quinazolineacetic acids and related analogues as aldose reductase inhibitors.
AID187320Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 122003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID189586Effect of the treatment on day 16 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID1465692Inhibition of human AKR1B1 assessed as decrease in glyceraldehyde reduction2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
AID242668In vitro inhibition of recombinant human aldose reductase expressed in Escherichia coli2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID34358In vitro inhibition of aldose reductase from the partially purified bovine lens at 10e-7 M concentration1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
(Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors.
AID91121Compound was tested for the inhibition of sorbitol accumulation in washed human erythrocytes.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID203733Inhibition of sorbitol dehydrogenase from sheep liver (40 U/mg of protein)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors.
AID318821Inhibition of retinaldehyde reductase activity of human AKR1B10 expressed in COS7 cells at 1 uM relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID187327Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 192003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID187321Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 132003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID34964Inhibitory activity measured against rat lens aldose reductase using 3-pyridinecarboxaldehyde as substrate1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID468487Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 19 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID187323Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 152003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID489642Selectivity ratio of IC50 for human ALR to IC50 for human AR2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID318837Inhibition of rat AKR1B42007Proceedings of the National Academy of Sciences of the United States of America, Dec-26, Volume: 104, Issue:52
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
AID182590In vivo inhibition of sorbitol accumulation in rat sciatic nerves at 5*10e-6 M concentration1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
AID367705Inhibition of human recombinant ALR2 expressed in bacterial cell expression system2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID34476Inhibition of aldose reductase in partially purified bovine lens preparation at 10e-7 M concentration1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
AID408630Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 14 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID188540In vivo inhibition of polyol accumulation in galactosemic rat diaphragm at dose 6 mg/kg administered perorally1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
(Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors.
AID468491Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QID after 13 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID489638Inhibition of N-terminal 6His-tagged human aldose reductase expressed in Escherichia coli BL21(DE3) mediated NADPH linked pyridine-3-aldehyde reduction2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID176722Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 4 days in lens1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
AID367708Inhibition of pig ALR1 by Uncompetitive inhibition based Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID182415In vivo inhibition of galactitol accumulation in the diaphragm of rat vat a dose of 6 mg/kg/day1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
AID189606Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 192003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID408634Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 18 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID468483Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 15 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID34205In vitro inhibition of aldose reductase activity in a partially purified bovine lens preparation1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID188552In vivo inhibition of polyol accumulation in galactosemic rat nerve at dose 6 mg/kg administered perorally1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
(Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors.
AID232928Selectivity as ratio of IC50 for rat lens and kidney aldose reductase1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID34637In vitro inhibitory activity against recombinant human aldose reductase (ALR2) was determined2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID489641Selectivity ratio of IC50 for human ALR to IC50 for AKR1B102010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID184013In vitro inhibition of sorbitol accumulation was measured in rat sciatic nerves incubated in the presence of 50 mM glucose at 10e-6 M concentration1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID252115Inhibition of sorbitol accumulation in lens of diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 10 mg/kg/day2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
AID187326Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 182003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID225460in vitro inhibition of galactitol accumulation in the sciatic nerve of rats fed 20% galactose for 4 day at 96 mg/kg/day dose1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Quinazolineacetic acids and related analogues as aldose reductase inhibitors.
AID34804In vitro inhibitory activity against aldose reductase (ALR2) from rat lens extraction.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID468490Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QID after 12 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID468489Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 21 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID189581Effect of the treatment on day 13 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID176748Dose required for inhibition of sorbital accumulation in the sciatic nerve of streptozotocin- induced diabetic rat.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
AID468492Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QID after 14 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID468488Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 20 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID468497Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QID after 19 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID187322Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 142003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID408631Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 15 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID181258inhibition of aldose reductase activity was measured by measuring galactose accumulation in the sciatic nerves of galactose fed rat.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID187318Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 212003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID187328Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 202003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID181259inhibition of aldose reductase activity was measured by measuring sorbitor accumulation in the sciatic nerves of STZ diabetic rat.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID189603Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 162003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID34179Selectivity ratio measured as the IC50 ratio of aldehyde/aldose reductase values1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID367703Inhibition of human recombinant ALR2 expressed in bacterial cell expression system by Uncompetitive inhibition based Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID34326In vitro inhibition of bovine lens aldose reductase1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Computer-assisted design and synthesis of novel aldose reductase inhibitors.
AID189580Effect of the treatment on day 13 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID189595Effect of the treatment on day 20 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID697009Inhibition of reductase activity of N-terminal 6His-tagged human AKR1B10 expressed in Escherichia coli BL21(DE3) assessed as pyridine-3-aldehyde reduction2011Journal of natural products, May-27, Volume: 74, Issue:5
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
AID241043Inhibition of aldose reductase from pig lenses2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Soft docking and multiple receptor conformations in virtual screening.
AID75439In vitro inhibitory activity against glutathione reductase (GR) from bakers yeast; Not active2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID189577Effect of the treatment on day 11 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID489631Inhibition of reductase activity of N-terminal 6His-tagged AKR1B10 expressed in Escherichia coli BL21(DE3) assessed as inhibition of NADPH linked pyridine-3-aldehyde reduction2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID34812Inhibition of aldose reductase (or polyol accumulation) in isolated rat sciatic nerve by compound at 10e-5 M concentration1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Computer-assisted design and synthesis of novel aldose reductase inhibitors.
AID367707Selectivity ratio of IC50 for pig ALR1 to IC50 for human recombinant ALR22009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID232953Inhibitory activity measured against pig kidney aldehyde reductase using 3-pyridinecarboxaldehyde as substrate1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
AID181882In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in sciatic nerve at 6 mg/Kg/day1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
AID182939In vivo inhibition of polyol accumulation in galactosemic rats nerve1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
(Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors.
AID34780Inhibition of pig kidney aldose reductase (ALR2)2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Rational design of an indolebutanoic acid derivative as a novel aldose reductase inhibitor based on docking and 3D QSAR studies of phenethylamine derivatives.
AID184361In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in lens at 6 mg/Kg/day; NS=Not significant (% Inhibition)1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
AID75435Evaluated for inhibition of glutathione reductase.; No inhibition1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors.
AID35131Inhibitory activity against aldose reductase enzyme2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
AID34339inhibition of aldose reductase activity was measured on partially purified bovine lens preparations incubated in presence of 50 mM glucose.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID468496Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QID after 18 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID176723Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 4 days in sciatic nerve1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
AID176718Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 12 days in sciatic nerve1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
AID34505Inhibition of bovine lens aldose reductase with DL-glyceraldehyde as substrate1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.
AID176717Dose at which the tissue level of polyol accumulation was reduced by 50% was evaluated for 12 days in lens1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID182579In vivo inhibition of sorbitol accumulation in rat sciatic nerves at 10e-5 M concentration1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
AID189579Effect of the treatment on day 12 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID182937In vivo inhibition of polyol accumulation in galactosemic rats diaphragm1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
(Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors.
AID187324Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 162003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID189585Effect of the treatment on day 15 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID182214In vivo inhibition of galactitol accumulation in diaphragm of rat at 6 mg/kg/day1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID408633Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 17 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID408628Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 12 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID35134Evaluated for inhibition of Aldose reductase 21996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors.
AID182938In vivo inhibition of polyol accumulation in galactosemic rats lens1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
(Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors.
AID179963Inhibition of galactitol accumulation in rat RBC incubated in presence of 50 mM glucose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID34196Evaluated for inhibition of Aldehyde reductase 11996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID230205Inhibitory Activity ratio (IC50 ratio) calculated by Human recombinant aldose reductase wild type against Mutant Aldose reductase (W20Y)2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID189589Effect of the treatment on day 17 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID179964Inhibition of galactitol accumulation in rat lens incubated in presence of 50 mM glucose1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID182584In vivo inhibition of sorbitol accumulation in rat sciatic nerves at 10e-6 M concentration1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
AID34199In vitro inhibitory activity against aldehyde reductase 1 (ALR1) from rat kidney.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID468495Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QID after 17 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID468480Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 12 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID489639Inhibition of N-terminal 6His-tagged human aldehyde reductase expressed in Escherichia coli BL21(DE3) mediated D-glucuronate reduction2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
AID189594Effect of the treatment on day 20 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID468485Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 17 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID34627Compound was evaluated In vitro for inhibition of aldose reductase activity by 50% in dog RBC1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
AID189590Effect of the treatment on day 18 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID189599Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 122003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID408380Inhibition of ALR2 in Sprague-Dawley rat lens by spectrophotometry2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID322413Inhibition of human recombinant aldose reductase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.
AID189605Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 182003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID173583Dose that decreased galactitol accumulation by 50% in the sciatic nerve in the galactosemic rat model after administration for 4 days in the diet; 7.3+/-2.3 mg/(kg day)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.
AID184011In vitro inhibition of sorbitol accumulation was measured in rat sciatic nerves incubated in the presence of 50 mM glucose at 10e-5 M concentration1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID189578Effect of the treatment on day 12 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID189600Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 132003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID34355In vitro aldose reductase inhibitory activity measured by NADPH-dependent inhibition of glyceraldehyde reduction in a partially purified bovine lens preparation at 10E-7 M1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
AID187319Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 112003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID252120Inhibition of sciatic nerve sorbitol accumulation in diabetic rats (streptozotocin treated) done for 30 minutes at 22 degree C in dark by using sorbitol dehydrogenase at 10 mg/kg/day2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
AID189584Effect of the treatment on day 15 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID408635Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 19 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID34201Inhibitory Activity against Human recombinant Aldose Reductase (wild type)2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
AID179965Inhibition of galactitol accumulation in sciatic nerves of rat incubated in presence of 50 mM glucose.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID468499Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QIDafter 21 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID187325Ability to prevent cataract development in severly galactosemic rat treated with 3 percent ophthalmic solution on day 172003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID173585Dose that decreased sorbitol accumulation by 50% in the sciatic nerve in the galactosemic rat model after administration for 3 weeks in the diet; 4.8+/- 2.4 mg/(kg day)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.
AID1478798Inhibition of Sprague-Dawley rat kidney ALR1 using sodium D-glucuronate as substrate by spectrophotometric method2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.
AID468494Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QID after 16 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID468481Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 13 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID181257inhibition of aldose reductase activity was measured by measuring galactose accumulation in the RBC of galactose fed rat.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.
AID468482Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 3% ophthalmic solution administered topically QID after 14 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID34969Inhibitory concentration to aldose reductase (ALR-2) obtained from rat lens2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID468476Inhibition of Albino rat eye lens ALR2 assessed as NADPH oxidation by spectrophotometry2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID408636Prevention of cataract development in severely galactosemic Sprague-Dawley Albino rat assessed as lens opacification administered four timely daily as 3% eye-drop solution in precorneal region for 20 days by slit-lamp microscopy2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
AID468498Prevention of nuclear cataract development in severe galactosemic Albino rat assessed as nuclear cataract appearance at 1% ophthalmic solution administered topically QID after 20 days by slit-lamp microscopy2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
AID34357In vitro inhibition of aldose reductase from the partially purified bovine lens at 10e-6 M concentration1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
(Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors.
AID189582Effect of the treatment on day 14 with ophthalmic solution (1%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID367704Inhibition of pig ALR12009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
AID177265Compound was evaluated for the ED50(chronic) in male Sprague-Dawley rats(n=4) treated with streptozotocin (85 mg/kg intravenously).1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
AID1465691Inhibition of human N-terminal His-tagged AKR1B10 expressed in Escherichia coli BL21 using retinaldehyde as substrate2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
AID34356In vitro inhibition of aldose reductase from the partially purified bovine lens at 10e-5 M concentration1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
(Pyrimidinyloxy)acetic acids and pyrimidineacetic acids as a novel class of aldose reductase inhibitors.
AID189591Effect of the treatment on day 18 with ophthalmic solution (3%)on development of nuclear cataract in severely galactosemic rats2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.
AID182566In vivo inhibition of galactitol accumulation in the sciatic nerves of rat at a dose of 6 mg/kg/day1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Orally active aldose reductase inhibitors derived from bioisosteric substitutions on tolrestat.
AID189601Ability to prevent cataract development in severly galactosemic rat treated with 1 percent ophthalmic solution on day 142003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
AID1478797Inhibition of Sprague-Dawley rat lens ALR2 using D,L-glyceraldehyde as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by spectrophotometric method2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.
AID1802104IC50-Activity Assay (AKR1B10) from Article 10.1021/acschembio.6b00382: \\IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors\\
AID1802103IC50-Activity Assay (AR) from Article 10.1021/acschembio.6b00382: \\IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors\\
AID1797506Enzyme Inhibition Assay from Article 10.1021/jm0492094: \\Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabet2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
AID1346211Human aldo-keto reductase family 1 member B (1.-.-.- Oxidoreductases)2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (179)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (17.32)18.7374
1990's91 (50.84)18.2507
2000's39 (21.79)29.6817
2010's16 (8.94)24.3611
2020's2 (1.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.88 (24.57)
Research Supply Index5.41 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials25 (12.63%)5.53%
Reviews19 (9.60%)6.00%
Case Studies1 (0.51%)4.05%
Observational0 (0.00%)0.25%
Other153 (77.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]